Logo image of ALEMG.PA

LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis

EPA:ALEMG - Euronext Paris - Matif - FR0000075343 - Common Stock - Currency: EUR

4.08  -0.11 (-2.63%)

Fundamental Rating

3

Taking everything into account, ALEMG scores 3 out of 10 in our fundamental rating. ALEMG was compared to 59 industry peers in the Health Care Equipment & Supplies industry. The financial health of ALEMG is average, but there are quite some concerns on its profitability. ALEMG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ALEMG had negative earnings in the past year.
In multiple years ALEMG reported negative net income over the last 5 years.
In multiple years ALEMG reported negative operating cash flow during the last 5 years.
ALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

Looking at the Return On Assets, with a value of 27.66%, ALEMG belongs to the top of the industry, outperforming 98.31% of the companies in the same industry.
The Return On Equity of ALEMG (57.02%) is better than 100.00% of its industry peers.
Industry RankSector Rank
ROA 27.66%
ROE 57.02%
ROIC N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ALEMG.PA Yearly ROA, ROE, ROICALEMG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

ALEMG has a better Profit Margin (24.05%) than 91.53% of its industry peers.
Looking at the Gross Margin, with a value of 31.89%, ALEMG is doing worse than 79.66% of the companies in the same industry.
ALEMG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 24.05%
GM 31.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
ALEMG.PA Yearly Profit, Operating, Gross MarginsALEMG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

5

2. Health

2.1 Basic Checks

ALEMG has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.
ALEMG has a better debt/assets ratio than last year.
ALEMG.PA Yearly Shares OutstandingALEMG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ALEMG.PA Yearly Total Debt VS Total AssetsALEMG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ALEMG has an Altman-Z score of 1.69. This is a bad value and indicates that ALEMG is not financially healthy and even has some risk of bankruptcy.
ALEMG has a Altman-Z score of 1.69. This is comparable to the rest of the industry: ALEMG outperforms 40.68% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that ALEMG is not too dependend on debt financing.
ALEMG has a Debt to Equity ratio of 0.41. This is comparable to the rest of the industry: ALEMG outperforms 49.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACCN/A
ALEMG.PA Yearly LT Debt VS Equity VS FCFALEMG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

ALEMG has a Current Ratio of 3.47. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 3.47, ALEMG belongs to the best of the industry, outperforming 83.05% of the companies in the same industry.
ALEMG has a Quick Ratio of 2.57. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.57, ALEMG belongs to the top of the industry, outperforming 84.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.47
Quick Ratio 2.57
ALEMG.PA Yearly Current Assets VS Current LiabilitesALEMG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ALEMG have decreased strongly by -178.48% in the last year.
The Revenue for ALEMG has decreased by -38.33% in the past year. This is quite bad
ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.02% yearly.
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.68%
Revenue 1Y (TTM)-38.33%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%-47.27%

3.2 Future

Based on estimates for the next years, ALEMG will show a small growth in Earnings Per Share. The EPS will grow by 7.07% on average per year.
Based on estimates for the next years, ALEMG will show a very negative growth in Revenue. The Revenue will decrease by -18.80% on average per year.
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALEMG.PA Yearly Revenue VS EstimatesALEMG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALEMG.PA Yearly EPS VS EstimatesALEMG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 9.14, the valuation of ALEMG can be described as reasonable.
ALEMG's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALEMG is cheaper than 93.22% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. ALEMG is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.14
ALEMG.PA Price Earnings VS Forward Price EarningsALEMG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEMG.PA Per share dataALEMG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALEMG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LABORATOIRES EUROMEDIS

EPA:ALEMG (6/17/2025, 7:00:00 PM)

4.08

-0.11 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-24 2025-04-24/amc
Earnings (Next)10-27 2025-10-27
Inst Owners1.67%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.71M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.14
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)0.45
Fwd EY10.94%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS18.22
BVpS7.69
TBVpS7.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.66%
ROE 57.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 24.05%
GM 31.89%
FCFM N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.47
Quick Ratio 2.57
Altman-Z 1.69
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.68%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.33%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%-47.27%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A